SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (498)3/20/1997 12:56:00 PM
From: Webhead   of 1762
 
Thanks for your reply. I did know that a subset of IDEC's antibodies were humanized and not primatized and I gather from your post that the licensing seems to involve only the former. Since IDEC has patent protection for primatized antibodies I was concerned that if their patent was seen as infringing on PDL's a significant chunk of their own revinues would be spent as royalties. Additionally, I was hoping that IDEC would be able to set itself up in competition with PDL for licensing antibodies that would not give a host vs. antibody reaction like the prodution of human antimouse antibodys that hinders the activity of many monoclonals (I think that the actual amino acid sequence used in "primatizing" the antibodies was identical to the human sequence so I'm not sure if this would constitute an infringment. I suppose it would depend on whethor the sequence of amino acids or the origin of the sequence is viewed as the "invention" in these cases.)

Ed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News